share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024财年三季报
美股SEC公告 ·  2024/10/31 15:46

Moomoo AI 已提取核心信息

Bristol-Myers Squibb reported Q3 2024 revenues of $11.9 billion, up 8% year-over-year, driven by strong performance from its Growth Portfolio and Eliquis. Net earnings were $1.2 billion with diluted EPS of $0.60, compared to $1.9 billion and $0.93 EPS in Q3 2023. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.8 billion.The company achieved significant regulatory milestones, including FDA approval of Cobenfy for schizophrenia and expanded approvals for Breyanzi in multiple indications. Operating expenses increased primarily due to recent acquisitions, with R&D expenses up 6% to $2.4 billion and amortization of acquired intangible assets rising 7% to $2.4 billion.BMS maintained strong liquidity with $7.9 billion in cash and cash equivalents while completing strategic acquisitions of Karuna, RayzeBio and Mirati. The company issued $13 billion in senior unsecured notes to partially fund these acquisitions. Operating cash flow remained robust at $10.8 billion year-to-date, supporting continued dividend payments of $3.6 billion.
Bristol-Myers Squibb reported Q3 2024 revenues of $11.9 billion, up 8% year-over-year, driven by strong performance from its Growth Portfolio and Eliquis. Net earnings were $1.2 billion with diluted EPS of $0.60, compared to $1.9 billion and $0.93 EPS in Q3 2023. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.8 billion.The company achieved significant regulatory milestones, including FDA approval of Cobenfy for schizophrenia and expanded approvals for Breyanzi in multiple indications. Operating expenses increased primarily due to recent acquisitions, with R&D expenses up 6% to $2.4 billion and amortization of acquired intangible assets rising 7% to $2.4 billion.BMS maintained strong liquidity with $7.9 billion in cash and cash equivalents while completing strategic acquisitions of Karuna, RayzeBio and Mirati. The company issued $13 billion in senior unsecured notes to partially fund these acquisitions. Operating cash flow remained robust at $10.8 billion year-to-date, supporting continued dividend payments of $3.6 billion.
施贵宝公布2024年第三季度营业收入为119亿，同比增长8%，主要受到其增长投资组合和Eliquis的强劲表现推动。净收益为12亿，摊薄后每股收益为0.60美元，而2023年第三季度为19亿和0.93美元的每股收益。增长投资组合，包括Opdivo、Orencia和Yervoy，营业收入增长18%，达到58亿。公司实现了重要的监管里程碑，包括FDA批准Cobenfy用于治疗精神分裂症，并在多个适应症上扩大了对于Breyanzi的批准。营业费用主要由于近期收购而增加，研发费用增长6%，达到24亿，收购无形资产的摊销增加7%，达到24亿。BMS保持强大的流动性，现金及现金等价物为79亿，同时完成了对Karuna、RayzeBio和Mirati的战略收购。公司发行了130亿的高级无担保票据以部分资助这些收购。今年至今，营业现金流强劲，达到108亿，支持持续的36亿现金分红支付。
施贵宝公布2024年第三季度营业收入为119亿，同比增长8%，主要受到其增长投资组合和Eliquis的强劲表现推动。净收益为12亿，摊薄后每股收益为0.60美元，而2023年第三季度为19亿和0.93美元的每股收益。增长投资组合，包括Opdivo、Orencia和Yervoy，营业收入增长18%，达到58亿。公司实现了重要的监管里程碑，包括FDA批准Cobenfy用于治疗精神分裂症，并在多个适应症上扩大了对于Breyanzi的批准。营业费用主要由于近期收购而增加，研发费用增长6%，达到24亿，收购无形资产的摊销增加7%，达到24亿。BMS保持强大的流动性，现金及现金等价物为79亿，同时完成了对Karuna、RayzeBio和Mirati的战略收购。公司发行了130亿的高级无担保票据以部分资助这些收购。今年至今，营业现金流强劲，达到108亿，支持持续的36亿现金分红支付。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    施贵宝
    BMY
    -- 60.020
    默沙东
    MRK
    -- 89.230
    赛诺菲安万特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯维公司
    ABBV
    -- 205.290
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点